false --12-31 Q3 0001549631 0001549631 2026-01-01 2026-09-30 0001549631 2026-11-16 0001549631 2026-09-30 0001549631 2025-12-31 0001549631 us-gaap:RelatedPartyMember 2026-09-30 0001549631 us-gaap:RelatedPartyMember 2025-12-31 0001549631 QURT:QuartaRadIncMember 2026-07-01 2026-09-30 0001549631 QURT:QuartaRadIncMember 2025-07-01 2025-09-30 0001549631 QURT:QuartaRadIncMember 2026-01-01 2026-09-30 0001549631 QURT:QuartaRadIncMember 2025-01-01 2025-09-30 0001549631 QURT:SellavirIncMember 2026-07-01 2026-09-30 0001549631 QURT:SellavirIncMember 2025-07-01 2025-09-30 0001549631 QURT:SellavirIncMember 2026-01-01 2026-09-30 0001549631 QURT:SellavirIncMember 2025-01-01 2025-09-30 0001549631 2026-07-01 2026-09-30 0001549631 2025-07-01 2025-09-30 0001549631 2025-01-01 2025-09-30 0001549631 us-gaap:CommonStockMember 2025-12-31 0001549631 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001549631 us-gaap:RetainedEarningsMember 2025-12-31 0001549631 us-gaap:CommonStockMember 2024-12-31 0001549631 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001549631 us-gaap:RetainedEarningsMember 2024-12-31 0001549631 2024-12-31 0001549631 us-gaap:CommonStockMember 2026-06-30 0001549631 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001549631 us-gaap:RetainedEarningsMember 2026-06-30 0001549631 2026-06-30 0001549631 us-gaap:CommonStockMember 2025-06-30 0001549631 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001549631 us-gaap:RetainedEarningsMember 2025-06-30 0001549631 2025-06-30 0001549631 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001549631 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-09-30 0001549631 us-gaap:RetainedEarningsMember 2026-01-01 2026-09-30 0001549631 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001549631 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-30 0001549631 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-30 0001549631 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001549631 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001549631 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001549631 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001549631 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001549631 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001549631 us-gaap:CommonStockMember 2026-09-30 0001549631 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001549631 us-gaap:RetainedEarningsMember 2026-09-30 0001549631 us-gaap:CommonStockMember 2025-09-30 0001549631 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001549631 us-gaap:RetainedEarningsMember 2025-09-30 0001549631 2025-09-30 0001549631 us-gaap:NonrelatedPartyMember 2026-01-01 2026-09-30 0001549631 us-gaap:NonrelatedPartyMember 2025-01-01 2025-09-30 0001549631 us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0001549631 us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0001549631 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember QURT:SellavirCustomerMember 2026-07-01 2026-09-30 0001549631 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember QURT:SellavirCustomerMember 2026-01-01 2026-09-30 0001549631 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001549631 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001549631 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001549631 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001549631 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001549631 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2023-03-31 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2023-03-31 2023-03-31 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2026-09-30 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2025-12-31 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2026-07-01 2026-09-30 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2026-01-01 2026-09-30 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2025-07-01 2025-09-30 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2025-01-01 2025-09-30 0001549631 QURT:ThaiCorporationMember 2023-05-31 0001549631 QURT:ThaiCorporationMember 2024-01-01 2024-01-31 0001549631 QURT:ThaiCorporationMember QURT:SellavirIncMember 2024-01-01 2024-01-31 0001549631 QURT:SecondNoteMember 2025-03-31 0001549631 QURT:ThaiCorporationMember 2026-09-30 0001549631 QURT:ThaiCorporationMember 2025-12-31 0001549631 QURT:NotesReceivableOneMember 2026-09-30 0001549631 QURT:SellavirConsultantsMember 2025-01-01 2025-01-31 0001549631 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0001549631 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001549631 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0001549631 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001549631 QURT:StarSystemsCorporationMember 2025-12-31 0001549631 QURT:StarSystemsCorporationMember 2026-09-30 0001549631 QURT:QuartaRadIncMember us-gaap:SoftwareDevelopmentMember 2017-07-31 0001549631 us-gaap:RelatedPartyMember QURT:QuartaRadIncMember 2026-09-30 0001549631 us-gaap:RelatedPartyMember QURT:QuartaRadIncMember 2025-12-31 0001549631 us-gaap:MajorityShareholderMember srt:ChiefExecutiveOfficerMember 2026-09-30 0001549631 us-gaap:MajorityShareholderMember srt:ChiefExecutiveOfficerMember 2025-12-31 0001549631 QURT:QuartaRadLtdMember 2026-01-01 2026-09-30 0001549631 QURT:SellavirIncMember 2026-01-01 2026-09-30 0001549631 QURT:QuartaRadLtdMember 2026-07-01 2026-09-30 0001549631 QURT:SellavirIncMember 2026-07-01 2026-09-30 0001549631 QURT:QuartaRadLtdMember 2025-01-01 2025-09-30 0001549631 QURT:SellavirIncMember 2025-01-01 2025-09-30 0001549631 QURT:QuartaRadLtdMember 2025-07-01 2025-09-30 0001549631 QURT:SellavirIncMember 2025-07-01 2025-09-30 0001549631 QURT:QuartaRadLtdMember 2026-09-30 0001549631 QURT:QuartaRadLtdMember 2025-12-31 0001549631 QURT:SellavirIncMember 2026-09-30 0001549631 QURT:SellavirIncMember 2025-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure QURT:Segment iso4217:THB

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ quarterly REPORT under SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2026

 

or

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______

 

Commission File No. 000-55964

 

Quarta-Rad, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   45-4232089
(State or other Jurisdiction of
Incorporation or Organization)
  (I.R.S. Employer
Identification No.)
     
1201 N. Orange St., Suite 700    
Wilmington, DE   19801
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (302) 887-9916

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, par value $0.0001 per share

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated file,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☒ Smaller reporting company ☒
   
Emerging Growth company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐ No ☒

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section l2, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

 

Yes ☐ No ☐

 

APPLICABLE ONLY TO CORPORATE ISSUERS

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of November 16, 2026, the number of shares outstanding of the issuer’s sole class of common stock, $0.0001 par value per share, is 15,899,483.

 

 

 

 

 

 

table of contents

 

Part I – FINANCIAL INFORMATION  
Item 1. Financial Statements (unaudited)  
Condensed and Consolidated Balance Sheets 3
Condensed and Consolidated Statements of Operations 4
Condensed and Consolidated Statements of Stockholders’ Equity (Deficit) 5
Condensed and Consolidated Statements of Cash Flows 7
Notes to the Condensed and Consolidated Unaudited Financial Statements 8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
Item 3. Quantitative and Qualitative Disclosures about Market Risk 22
Item 4. Controls and Procedures 22
PART II — OTHER INFORMATION 23
Item 1. Legal Proceedings 23
Item 1A. Risk Factors 23
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23
Item 3. Defaults Upon Senior Securities 23
Item 4. Mine Safety Disclosures 23
Item 5. Other Information 23
Item 6. Exhibits 23
Signatures 24

 

2

 

 

QUARTA-RAD, INC. AND SUBSIDIARIES

CONDENSED AND CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

         
   As of 
   September 30, 2026   December 31, 2025 
ASSETS          
Current Assets          
Cash  $19,955   $72,909 
Accounts receivable - related party   5,000    - 
Marketable securities, trading   3    3 
Notes receivable - related party - current portion   31,625    - 
Total Current Assets   56,583    72,912 
           
Other Assets          
Notes receivable - related party, net of current portion
and discount of $4,808 and $7,214 at September 30, 2026 and December 31, 2025
   216,510    263,970 
Interest receivable - related party   52,208    52,208 
Trade receivable, net of discount of $12,071 and $14,639 at September 30, 2026 and December 31, 2025   26,989    24,421 
Total Other Assets   295,707    340,599 
           
TOTAL ASSETS  $352,290   $413,511 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
           
Current Liabilities          
Accounts payable and accrued expenses  $12,900   $17,100 
Payables and accrued expenses - related parties   378,311    272,429 
Total Current Liabilities   391,211    289,529 
           
Commitments and Contingencies - Note 8   -    - 
           
Stockholders’ Equity (Deficit)          
Common stock $0.0001 par value; 50,000,000 shares authorized; 15,899,483 issued and outstanding at September 30, 2026 and December 31, 2025   1,591    1,591 
Additional paid-in capital   569,329    550,776 
Accumulated deficit   (609,841)   (428,385)
Total Stockholders’ Equity (Deficit)   (38,921)   123,982 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)  $352,290   $413,511 

 

See accompanying notes to unaudited condensed and consolidated financial statements.

 

3

 

 

QUARTA-RAD, INC. AND SUBSIDIARIES

CONDENSED AND CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   For the three months ended September 30, 2026   For the three months ended September 30, 2025   For the nine months ended September 30, 2026   For the nine months ended September 30, 2025 
                 
Sales -Quarta Rad, Inc., net  $906   $2,469   $2,618   $7,686 
Sales - Sellavir, Inc., net - related party   39,000    60,000    127,000    155,000 
                     
Total Sales, net   39,906    62,469    129,618    162,686 
                     
Cost of goods sold - Quarta-Rad, Inc.   348    974    348    3,809 
Cost of goods sold - Sellavir Inc.   24,080    32,708    86,940    93,722 
                     
Gross profit   15,478    28,787    42,330    65,155 
                     
Expenses:                    
General and administrative   34,748    75,046    134,121    226,992 
Professional and consulting fees   21,200    19,701    73,830    80,588 
Operating expenses   55,948    94,747    207,951    307,580 
                     
Net loss from operations   (40,470)   (65,960)   (165,621)   (242,425)
Other income - interest and dividends   -    -    -    6 
Other income - foreign currency transaction gain/(loss)   (2,826)   1,415    (18,241)   15,868 
Other income - interest - related party   802    802    2,406    13,307 
Other income - unrealized gain(loss) on investments   1    2    -    (1)
Net loss before provision for income taxes   (42,493)   (63,741)   (181,456)   (213,245)
                     
Income tax expense   -    2,900    -    2,900 
                     
Net loss  $(42,493)  $(66,641)  $(181,456)  $(216,145)
                     
Loss per share - basic and diluted  $(0.00)  $(0.00)  $(0.01)  $(0.01)
                     
Weighted average shares - basic and diluted   15,899,483    15,899,483    15,899,483    15,877,744 

 

See accompanying notes to unaudited condensed and consolidated financial statements.

 

4

 

 

QUARTA-RAD, INC. AND SUBSIDIARIES

CONDENSED AND CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the nine months ended September 30, 2026

(Unaudited)

 

                      
   Common Stock   Additional       Total 
   Shares   Amount  

Paid-In

Capital

  

Accumulated

Deficit

  

Stockholders’

Equity (Deficit)

 
Balance, December 31, 2025   15,899,483   $1,591   $550,776   $(428,385)  $123,982 
Net loss   -    -    -    (181,456)   (181,456)
Stock based compensation   -    -    18,553    -    18,553 
Balance, September 30, 2026   15,899,483   $1,591   $569,329   $(609,841)  $(38,921)

 

CONDENSED AND CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the nine months ended September 30, 2025

(Unaudited)

 

   Common Stock   Additional       Total 
   Shares   Amount  

Paid-In

Capital

  

Accumulated

Deficit

  

Stockholders’

Equity

 
Balance, December 31, 2024   15,674,483   $1,568   $346,726   $(171,456)  $176,838 
Net loss   -    -    -    (216,145)   (216,145)
Stock based compensation   225,000    23    148,394    -    148,417 
Balance, September 30, 2025   15,899,483   $1,591   $495,120   $(387,601)  $109,110 

 

See accompanying notes to unaudited condensed and consolidated financial statements.

 

5

 

 

QUARTA-RAD, INC. AND SUBSIDIARIES

CONDENSED AND CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the three months ended September 30, 2026

(Unaudited)

 

   Common Stock   Additional       Total 
   Shares   Amount  

Paid-In

Capital

  

Accumulated

Deficit

  

Stockholders’

Equity (Deficit)

 
Balance, June 30, 2026   15,899,483   $1,591   $569,329   $(567,348)  $3,572 
Net loss   -    -    -    (42,493)   (42,493)
Balance, September 30, 2026   15,899,483   $1,591   $569,329   $(609,841)  $(38,921)

 

CONDENSED AND CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the three months ended September 30, 2025

(Unaudited)

 

   Common Stock   Additional      Total 
   Shares   Amount  

Paid-In

Capital

   Accumulated Deficit  

Stockholders’

Equity

 
Balance, June 30, 2025   15,899,483   $1,591   $439,464   $(320,960)  $120,095 
Net loss                  (66,641)   (66,641)
Stock based compensation   -    -    55,656    -    55,656 
Balance, September 30, 2025   15,899,483   $1,591   $495,120   $(387,601)  $109,110 

 

See accompanying notes to unaudited condensed and consolidated financial statements.

 

6

 

 

QUARTA-RAD, INC. AND SUBSIDIARIES

CONDENSED AND CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   For the nine months ended September 30, 2026   For the nine months ended September 30, 2025 
         
OPERATING ACTIVITIES:          
Net loss  $(181,456)  $(216,145)
           
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   -    600 
Stock based compensation   18,553    148,417 
Foreign currency transaction (gain)/loss   18,241    (15,868)
Amortization of note discount   (2,406)   (2,406)
Amortization of receivable discount   (2,568)   (2,568)
Net unrealized loss on investments   -    1 
Changes in operating assets and liabilities:          
Accounts receivable   -    (260)
Accounts receivable - related party   (5,000)   - 
Inventory   -    3,060 
Accrued interest receivable - related party   -    (10,901)
Accounts payable and accrued expenses   (4,200)   14,751 
Related party payable   105,882    51,406 
Net cash used in operating activities   (52,954)   (29,913)
           
Net change in cash   (52,954)   (29,913)
Cash, beginning of period   72,909    63,021 
Cash, end of period  $19,955   $33,108 
           
Supplemental Disclosure of Non-Cash Investing and Financing Activities          
           
Transfer of note receivable - related party at carrying value to officer in settlement of loan payable and accrued expenses:  $-   $199,375 
           
Supplemental cash flow information:          
           
Cash paid for interest  $-   $- 
           
Cash paid for income taxes  $-   $2,900 

 

See accompanying notes to unaudited condensed and consolidated financial statements.

 

7

 

 

QUARTA-RAD, INC. AND SUBSIDIARIES

 

Notes to the unaudited Condensed and Consolidated Financial Statements

 


NOTE 1 - BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements of Quarta-Rad, Inc. and subsidiaries (the “Company”) as of September 30, 2026, and for the three and nine months ended September 30, 2026 and 2025, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”).

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial position as of September 30, 2026, and the results of operations and cash flows for the periods presented. The condensed consolidated balance sheet as of December 31, 2025 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations for interim reporting. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Interim results are not necessarily indicative of the results that may be expected for the full fiscal year or any future interim period.

 

Beginning in 2024, the Company significantly reduced and began winding down its legacy radiation detection equipment business and shifted its primary operational focus to Sellavir, Inc., its wholly owned subsidiary. Sellavir is focused on the development and commercialization of artificial intelligence-driven software solutions for the call center and customer engagement industry, including the CenterEye platform.

 

The Company has experienced recurring operating losses and negative cash flows from operations and had an accumulated deficit of $609,841 as of September 30, 2026. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the issuance date of these financial statements. Management’s plans include continued development and commercialization of the Company’s software platforms, expansion of strategic partnerships, pursuit of additional customer engagements, and raising additional capital, if necessary. There can be no assurance that these plans will be successful.

 

The Company’s majority shareholder has historically provided financial support for operations and may continue to provide additional support, as needed. In addition, the Company is evaluating strategic alternatives related to its legacy operations, including a potential separation or spin-off of certain historical business activities; however, no definitive transaction has been approved or completed as of the filing date of this report.

 

NOTE 2 - NATURE OF BUSINESS

 

Quarta-Rad, Inc. (the “Company”) was historically engaged in the distribution of radiation detection devices, including Geiger counters, to consumers and commercial customers in North America and Europe. Beginning in 2024, the Company significantly reduced and began winding down these legacy operations, and such activities are no longer expected to represent a significant component of the Company’s future business.

 

The Company’s primary operational focus has shifted to Sellavir, Inc. (“Sellavir”), its wholly owned subsidiary. Sellavir is an artificial intelligence and analytics company focused on developing software solutions for the call center and customer engagement industry. Sellavir’s core product, CenterEye, is a software platform designed to leverage AI and advanced analytics to improve call center operations, enhance customer engagement, and support operational efficiencies through integration with major cloud-based contact center platforms.

 

The Company intends to continue developing and commercializing the CenterEye platform and related AI-driven software solutions as its principal business strategy.

 

8

 

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Quarta-Rad, Inc. and its wholly-owned subsidiary Sellavir, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Reclassifications

 

Certain amounts in the December 31, 2025 consolidated balance sheet have been reclassified to conform to the September 30, 2026 presentation. These reclassifications relate to the presentation of related party payables and had no effect on total liabilities, stockholders’ deficit, or previously reported net loss.

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods.

 

Significant estimates made by management include, among others, the recognition of revenue from related party arrangements and the recoverability of related party receivables and notes receivable. The Company bases its estimates on historical experience, knowledge of current conditions, and assumptions believed to be reasonable under the circumstances. The Company reviews its estimates on an ongoing basis. Actual results may differ materially from those estimates.

 

Notes Receivable – related party

 

Notes Receivable – related party consists of loan agreements entered into by Sellavir discussed in Note 4. Amounts receivable are remeasured into the functional currency at the balance sheet date where the Company records foreign transaction gain or loss. The Company’s functional currency is the United States Dollar.

 

Concentration of Credit Risk

 

The Company is exposed to credit risk primarily through its related-party accounts receivable, related-party notes receivable and accrued interest, and long-term trade receivables. The Company evaluates these financial assets for expected credit losses in accordance with ASC 326, Financial Instruments—Credit Losses, considering historical collection experience, the financial condition of counterparties, current economic conditions, and reasonable and supportable forecasts of future conditions.

 

At September 30, 2026, the Company had related-party accounts receivable of $5,000, related-party notes receivable with a net carrying amount of $248,135, accrued interest receivable of $52,208, and a long-term trade receivable with a net carrying amount of $26,989.

 

The Company ceased accruing interest on its remaining related party note effective March 31, 2025, due to uncertainty regarding collectability. Management continues to evaluate the recoverability of these balances and the need for an allowance for expected credit losses.

 

One related party customer accounted for all Sellavir revenue for the three and nine months ended September 30, 2026 and 2025. Related party accounts receivable were $5,000 at September 30, 2026 and there was no accounts receivable at December 31, 2025. Sellavir revenue represented 98% and 98% of consolidated revenue for the three and nine months ended September 30, 2026, respectively.

 

Earnings per Share

 

The Company’s basic earnings per share are calculated by dividing its net income available to common stockholders by the weighted average number of common shares outstanding for the period. The Company’s dilutive earnings per share is calculated by dividing its net income available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There were no potentially dilutive instruments outstanding during the periods ended September 30, 2026 and 2025.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 825, “Financial Instruments” include cash, trade accounts receivable, and accounts payable and accrued expenses. All instruments, except marketable securities are accounted for on a historical cost basis, which, due to the short maturity of these financial instruments, approximates fair value at September 30, 2026 and December 31, 2025. Marketable securities are level one assets recorded at fair value.

 

The carrying amounts of the Company’s cash, accounts payable, and other short-term financial instruments approximate their fair values due to their short-term maturities.

 

The Company’s long-term notes receivable and noncurrent trade accounts receivable are carried at amortized cost, net of any applicable allowance for credit losses. The fair values of these instruments are estimated using discounted cash flow analyses based on current market interest rates for instruments with similar terms and credit risks. Such estimates are classified within Level 3 of the fair value hierarchy under ASC 820, Fair Value Measurement. At September 30, 2026 and December 31, 2025, the carrying amounts of these instruments approximated their estimated fair values.

 

FASB ASC 820 “Fair Value Measurements and Disclosures” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

  ● Level 1. Observable inputs such as quoted prices in active markets;
     
  ● Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
     
  ● Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.

 

9

 

 

The Company’s investment securities consist of common and preferred stock. Substantially all the Company’s investments are Level 1. The fair market value is based on quoted prices in active markets for identical assets. Financial assets are measured at fair value on a recurring basis. The following table provides information at September 30, 2026 and December 31, 2025 about the Company’s financial assets measured at fair value on a recurring basis.

 

Values on September 30, 2026:

 

   Level 1   Level 2   Level 3   Total 
Assets at fair value:                    
Marketable securities  $3   $-   $-   $3 
                     
Total assets at fair value, September 30, 2026  $3   $-   $-   $3 

 

Values on December 31, 2025:

 

   Level 1   Level 2   Level 3   Total 
Assets at fair value:                    
Marketable securities  $3   $-   $-   $3 
                     
Total assets at fair value, December 31, 2025  $3   $-   $-   $3 

 

Revenue Recognition

 

The Company follows guidance from FASB Accounting Standards Codification ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The guidance sets forth a five-step revenue recognition model. The underlying principle of the standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services.

 

The Company generates revenue primarily from software development services, consulting services, and limited product sales associated with its legacy radiation detection business.

 

Revenue is measured based on consideration specified in a contract with a customer. A contract with a customer exists when we enter into an enforceable contract with a customer. The contract is based on either the acceptance of standard terms and conditions on the websites for e-commerce customers and via telephone with our third-party call center for our print media and direct mail customers, or the execution of terms and conditions contracts with retailers and wholesalers. These contracts define each party’s rights, payment terms and other contractual terms and conditions of the sale. Consideration is typically paid prior to shipment via credit card or check when our products are sold direct to consumers or approximately 30 days from the time control is transferred when sold to wholesalers, distributors and retailers. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience and, in some circumstances, published credit and financial information pertaining to the customer.

 

A performance obligation is a promise in a contract to transfer a distinct product to the customer, which for us is transfer of devices to our customers. Performance obligations promised in a contract are identified based on the goods that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract, whereby the transfer of the goods is separately identifiable from other promises in the contract. We have concluded the sale of goods and related shipping and handling are accounted for as the single performance obligation.

 

10

 

 

The transaction price of a contract is allocated to each distinct performance obligation and recognized as revenue when or as the customer receives the benefit of the performance obligation. The transaction price is determined based on the consideration to which we will be entitled to receive in exchange for transferring goods to the customer. We issue refunds to e-commerce and print media customers, upon request, within 30 days of delivery. We estimate the amount of potential refunds at each reporting period using a portfolio approach of historical data, adjusted for changes in expected customer experience, including seasonality and changes in economic factors. For retailers, distributors and wholesalers, we do not offer a right of return or refund, and revenue is recognized at the time products are shipped to customers. In all cases, judgment is required in estimating these reserves. Actual claims for returns could be materially different from the estimates. There was no reserve for sales returns and allowances at September 30, 2026 and December 31, 2025, respectively.

 

We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer when a product is shipped. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfilment cost and are included in cost of product sales.

 

We recognize consulting revenue over time as services are performed. Invoiced amounts are determined based on the level of work completed by contractors, measured against predetermined project milestones. These milestones are defined in the client contract and are tied to specific deliverables or stages in the agreed-upon project timeline.

 

Recent Accounting Pronouncements

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The update is intended to improve the navigability of the guidance in ASC 270 and clarify the applicability, form, content, and disclosure requirements for interim financial statements. The amendments also clarify that entities should disclose events and changes occurring since the end of the most recent annual reporting period that have a material impact on the entity. The guidance is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact this guidance may have on its consolidated financial statements and related disclosures.

 

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Topic 220-40): Disaggregation of Income Statement Expenses This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03, as clarified by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the impact of this standard on its financial statement presentation and disclosures.

 

Other recently issued accounting pronouncements not discussed above are not expected to have a material effect on the Company’s consolidated financial statements upon adoption.

 

Risks and Uncertainties

 

The Company is continuing to expand its artificial intelligence-driven software business through the development of new software platforms, consulting services, and AI-based solutions for the call center and customer engagement industry. Beginning in 2024, the Company significantly reduced its legacy radiation detection equipment business and shifted its primary operational focus to Sellavir and the development of the CenterEye platform.

 

The Company’s future success depends in part on its ability to successfully develop, commercialize, and achieve market acceptance of its AI-driven software products and services. The Company operates in a rapidly evolving and highly competitive industry characterized by changing technologies, evolving customer requirements, and frequent introductions of new products and services.

 

The success of the CenterEye platform depends on the Company’s ability to develop features that meet customer needs, maintain compatibility with third-party platforms, respond to technological advancements, and address software defects, cybersecurity risks, and operational challenges in a timely manner. There can be no assurance that the Company will successfully commercialize CenterEye or achieve significant market acceptance. Failure to do so could adversely affect the Company’s financial condition, results of operations, and future growth prospects.

 

11

 

 

NOTE 4–NOTE RECEIVABLE – RELATED PARTY

 

In March 2023, Sellavir entered into a loan agreement with a related Thai corporation for the purpose of purchasing land for development. In May 2023, the Company’s Chief Executive Officer and majority shareholder became the Chief Executive Officer and a minority shareholder of the Thai entity.

 

Under the terms of the agreement, the Thai corporation is obligated to repay Sellavir 9,000,000 Thai Baht (approximately $261,038 at inception), which includes a discount of $16,038, plus interest at a rate of 15% per annum.

 

The loan is denominated in Thai Baht and is remeasured at each reporting date. The total carrying value of the note was $248,135 and $263,970 as of September 30, 2026 and December 31, 2025, respectively. At September 30, 2026, $31,625 was classified as current and $216,510 as noncurrent. The Company recorded foreign currency transaction losses of $2,826 and $18,241 for the three and nine months ended September 30, 2026, respectively, compared with gains of $1,415 and $15,868 for the corresponding 2025 periods.

 

The unamortized amount related to the loan was $4,808 and $7,214 as of September 30, 2026 and December 31, 2025, respectively. Amortization included in related party interest income was $802 and $2,406 for the three and nine months ended September 30, 2026, respectively.

 

Pursuant to amendments in January 2024 and May 2025, principal payments are deferred until April 1, 2027, after which quarterly principal payments are due through April 1, 2031. Interest is payable at maturity. The loan is secured by land located in Thailand.

 

In May 2023, the Company issued an additional loan to the same related Thai corporation in the amount of $175,000, bearing interest at a rate of 15% per annum.

 

In January 2024, the loan agreement was amended to reduce the interest rate to 10% and to provide Sellavir with an additional 3% participation in the selling price of the underlying property. The amendment also included a one-year extension of all payment due dates.

 

QUARTA-RAD, INC. AND SUBSIDIARIES

 

Notes to the unaudited Condensed and Consolidated Financial Statements

 

During March 2025, the second note of $164,375 and accrued interest of $35,000, having an aggregate carrying amount of $199,375, was assigned to the Company’s CEO and majority shareholder in partial satisfaction of $199,375 of obligations owed to the CEO, consisting of $35,000 of accrued compensation and $164,375 of operating advances and expenses previously paid by the CEO, as discussed in Note 6. The assignment was effected at the carrying amounts of the respective assets and obligations, and no gain or loss was recognized on the transaction. At the time of the assignment, the CEO and majority shareholder was the Company’s sole director and approved the transaction. No independent valuation or fairness opinion was obtained in connection with the assignment. The assignment was documented pursuant to a written assignment agreement at the time of the transaction.

 

Accrued interest at September 30, 2026 and December 31, 2025 was $52,208 and is included as a long-term asset, interest receivable – related party. As of March 31, 2025, the Company ceased accruing interest income on the loan due to uncertainty regarding collectability.

 

Principal amounts to be received for the remaining note are set out below

 

   March 2023
Note
 
2027  $47,438 
2028   63,251 
2029   63,251 
2030   63,251 
2031   15,752 
Totals  $252,943 

 

12

 

 

NOTE 5–STOCKHOLDERS’ EQUITY (DEFICIT)

 

During January 2025, the Company issued 225,000 shares of restricted common stock to Sellavir consultants with an aggregate fair value of $222,625 based on the market value of the Company’s common stock on the grant dates. The shares were subject to a 12-month vesting period from the respective grant dates.

 

The Company recognized stock-based compensation expense of $0 and $18,553 for the three and nine months ended September 30, 2026, respectively, and $55,656 and $148,417 for the corresponding 2025 periods. The expense was included in general and administrative expenses. The shares were fully vested as of January 31, 2026.

 

NOTE 6–RELATED PARTY TRANSACTIONS

 

In May 2022, the Company began using Star Systems Corporation (“STAR”), a Japanese entity owned by the Company’s majority shareholder, as an intermediary to purchase inventory from Quarta-Rad, LTD (“QRR”), a company in Russia owned by a former minority shareholder who disposed of their interest in 2024. Amounts due to STAR were $42,502 as of both September 30, 2026 and December 31, 2025. The balances are due on demand and do not bear interest.

 

The Company made no inventory purchases through STAR from QRR during the three and nine months ended September 30, 2026 or 2025. The amounts payable to STAR and QRR have remained unchanged since December 31, 2024 and relate to transactions that occurred prior to the wind-down of the Company’s legacy product business.

 

QUARTA-RAD, INC. AND SUBSIDIARIES

 

Notes to the unaudited Condensed and Consolidated Financial Statements

 

In July 2017, the Company entered into a software development agreement with QRR related to a new radiation detection device for a total contract amount of $180,000. The development agreement expired on December 31, 2019. Amounts payable related to this agreement were $91,850 as of both September 30, 2026 and December 31, 2025. The balances are due on demand and do not bear interest.

 

In April 2021, the Company began compensating its Chief Executive Officer (“CEO”), who is also the Company’s majority shareholder. Accrued compensation due to the CEO totaled $141,000 and $117,000 as of September 30, 2026 and December 31, 2025, respectively, and is included in payables and accrued expenses – related parties in the accompanying balance sheets.

 

From time to time, the CEO has advanced funds on behalf of the Company for operating expenses. Total related party payables were $102,959 and $21,076 at September 30, 2026 and December 31, 2025.

 

As discussed in Note 4, during 2025 the Company assigned a related party note receivable and accrued interest held by Sellavir to the Company’s CEO in satisfaction of certain accrued compensation and operating advances owed to the CEO. See note 4 for additional details regarding this transaction.

 

Sellavir recognized software development and consulting revenue from STAR totaling $39,000 and $127,000 during the three and nine months ended September 30, 2026, respectively, compared with $60,000 and $155,000 in the corresponding 2025 periods. The Company’s CEO is also the majority shareholder of STAR.

 

The Company currently has two directors, Mr. Shvetsky and Mr. Choulindin. Mr. Choulindin, who was appointed to the Board of Directors on February 18, 2026, is Mr. Shvetsky’s half-brother and has served as the Company’s Director of Operations since December 2016. The Company has no independent directors and no audit committee.

 

See Note 4 for additional related party transactions.

 

NOTE 7–SEGMENTS

 

The Company has two operating segments through the operations of Quarta-Rad and Sellavir. The Company evaluates the performance of its segments based on revenues, operating income(loss) and net income(loss).

 

The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM regularly reviews the financial results of each operating segment, including revenues and operating income (loss), to assess performance and make decisions regarding the allocation of resources.

 

13

 

 

QUARTA-RAD, INC. AND SUBSIDIARIES

 

Notes to the unaudited Condensed and Consolidated Financial Statements

 

Segment information for the three and nine months ended September 30, 2026 and 2025 is as follows:

 

   Quarta-Rad   Sellavir   Consolidated 
For the nine months ended September 30, 2026
   Quarta-Rad   Sellavir   Consolidated 
Revenues  $2,618    127,000   $129,618 
Loss from operations   (75,665)   (89,956)   (165,621)
Net loss  $(75,665)   (105,791)  $(181,456)

 

   Quarta-Rad   Sellavir   Consolidated 
For the three months ended September 30, 2026
   Quarta-Rad   Sellavir   Consolidated 
Revenues  $906    39,000   $39,906 
Loss from operations   (21,596)   (18,874)   (40,470)
Net loss  $(21,596)   (20,897)  $(42,493)

 

   Quarta-Rad   Sellavir   Consolidated 
For the nine months ended September 30, 2025
   Quarta-Rad   Sellavir   Consolidated 
Revenues  $7,686   $155,000   $162,686 
Loss from operations   (126,095)   (116,330)   (242,425)
Net loss  $(126,095)  $(90,050)  $(216,145)

 

   Quarta-Rad   Sellavir   Consolidated 
For the three months ended September 30, 2025
   Quarta-Rad   Sellavir   Consolidated 
Revenues  $2,469   $60,000   $62,469 
Loss from operations   (28,234)   (37,726)   (65,960)
Net income/(loss)  $(28,234)  $(38,407)  $(66,641)

 

Total assets  As of September 30, 2026   As of December 31, 2025 
Quarta-Rad  $30,017   $31,851 
Sellavir   322,273    381,660 
Total assets  $352,290   $413,511 

 

NOTE 8– COMMITMENTS AND CONTINGENCIES

 

Contingencies

 

Legal

 

In the normal course of business, the Company may become involved in various legal proceedings. The Company is not aware of any pending or threatened legal proceedings to which the Company is or will be a party that, if successful, might result in material adverse change in the Company’s business, properties or financial condition.

 

NOTE 9–SUBSEQUENT EVENTS

 

The Company has performed an evaluation of events occurring subsequent to September 30, 2026, through November 16, 2026. Based on this evaluation, there is nothing to be disclosed.

 

14

 

 

Item 2. Management’s Discussion and Analysis of Financial Conditions and Results of Operations

 

The following is management’s discussion and analysis of financial condition and results of operations and is provided as a supplement to the accompanying unaudited condensed financial statements and notes to help provide an understanding of our financial condition, results of operations and cash flows during the periods included in the accompanying unaudited condensed financial statements.

 

In this Quarterly Report on Form 10-Q, “Company,” “the Company,” “us,” and “our” refer to Quarta-Rad, Inc., a Delaware corporation, unless the context requires otherwise.

 

We intend the following discussion to assist in the understanding of our financial position and our results of operations for the three and nine months ended September 30, 2026 and 2025. You should refer to the Financial Statements and related Notes in conjunction with this discussion.

 

Results of Operations

 

General

 

We were incorporated under the laws of the State of Delaware on November 29, 2011, with a fiscal year end of December 31. We were initially formed to distribute and sell radiation detection devices and related products to consumers and businesses in North America.

 

Beginning in 2013, we purchased products from Quarta-Rad, Ltd. (“QRR”), a company located in Russia, and shipped products to third-party online retailers and resellers for distribution. In recent periods, the Company has reduced its focus on its historical radiation detection product line and has shifted its primary business focus toward software development and AI-driven technologies.

 

During April 2020, we acquired Quarta-Rad USA, Inc., a Delaware corporation, as a wholly owned subsidiary. No consideration was paid for the shares. The purpose of the acquisition was to separate certain operations into a separate entity. Quarta-Rad USA was dissolved in 2022.

 

During December 2020, we acquired Sellavir, Inc. (“Sellavir”), an AI software company focused on advanced analytics, image processing, and call center software solutions. Sellavir’s technology platform is designed to assist organizations in analyzing video and operational data through proprietary AI technologies.

 

Sellavir has developed CenterEye, a software platform intended to simplify the use and management of cloud-based call center systems. CenterEye is designed to enhance call center operations through AI-driven analytics, automation, and operational monitoring capabilities.

 

Prior to April 2024, our chief executive officer and director, Victor Shvetsky, and our former director and president, Alexey Golovanov, were our only employees. In April 2024, Mr. Golovanov resigned from the Company.

 

The Company’s current focus is the continued development and commercialization of CenterEye and related AI-driven software solutions. Management is actively pursuing opportunities in the United States, Japan, and other international markets. The Company currently generates revenue primarily through relationships with its Japanese reseller associated with Sellavir’s software and development services.

 

Substantially all of the Company’s revenue is generated by Sellavir from software development and consulting services provided to Star Systems Corporation (“STAR”), a Japanese entity of which the Company’s Chief Executive Officer and majority shareholder is also the majority shareholder. STAR accounted for $39,000 of the Company’s $39,906 consolidated revenue for the three months ended September 30, 2026 (98%) and $127,000 of $129,618 for the nine months then ended (98%).

 

Because this revenue is derived from an entity under common control, the pricing and volume of these arrangements have not been established through arm’s-length negotiation and may not be indicative of the results the Company would achieve with unaffiliated customers. The Company has no contractual commitment from STAR with respect to future volumes, and STAR may reduce or discontinue its engagement of Sellavir at any time. The loss of this relationship would eliminate substantially all of the Company’s revenue. Investors should not assume that historical revenue from STAR is indicative of the Company’s ability to generate revenue from unaffiliated customers.

 

Our administrative office is located at 1201 N. Orange St., Suite 700, Wilmington, DE 19801.

 

Our business strategy is focused on expanding the development, marketing, and deployment of CenterEye and related technologies. We aim to enhance call center efficiency and customer engagement through AI-driven solutions while pursuing strategic relationships with businesses requiring advanced customer service and operational analytics platforms.

 

15

 

 

Sellavir Consulting

 

We expanded our operations through the acquisition of Sellavir in December 2020. Sellavir leverages its expertise in neural networks and artificial intelligence technologies to provide customized software development and AI-related services to clients. These services include image processing applications, operational analytics, and call center software solutions.

 

Our business model is focused on identifying customer-specific operational needs and developing software solutions to address those needs. Currently, the Company’s revenue associated with Sellavir operations is generated primarily through its Japanese reseller relationships.

 

The Company acquired Sellavir to:

 

● leverage Sellavir’s AI capabilities in connection with future technology initiatives;

 

● expand operations beyond the Company’s historical radiation detection product business; and

 

● pursue opportunities within the call center software industry through the development and commercialization of CenterEye.

 

CenterEye is intended to be offered as a subscription-based software platform, which management believes may provide recurring revenue opportunities in future periods. Sellavir began recognizing revenue related to call center software operations during 2024.

 

In January 2026, our subsidiary Sellavir entered into an Independent Software Vendor Partner Agreement with Genesys Cloud Services, Inc., under which Sellavir became a participant in the Genesys AppFoundry Program. The agreement does not provide for any minimum revenue, exclusivity, or guaranteed continuation, and we have generated no revenue under the agreement during the nine months ended September 30, 2026

 

The Company has two operating segments through the operations of Quarta-Rad and Sellavir. Net loss for the three months ended September 30, 2026, is comprised of:

 

   Quarta Rad   Sellavir   Total 
Sales  $906   $39,000   $39,906 
Cost of goods sold   348    24,080    24,428 
Gross profit   558    14,920    15,478 
                
Expenses:               
General & administrative   8,954    25,794    34,748 
Professional and consulting fees   13,200    8,000    21,200 
Operating expenses   22,154    33,794    55,948 
                
Net loss from operations   (21,596)   (18,874)   (40,470)
                
Other expense - foreign currency transaction loss        (2,826)   (2,826)
Other income - interest - related party   -    802    802 
Unrealized gain on investments   -    1    1 
                
Net loss  $(21,596)  $(20,897)  $(42,493)

 

16

 

 

The Company has two operating segments through the operations of Quarta-Rad and Sellavir. Net loss for the nine months ended September 30, 2026, is comprised of:

 

   Quarta Rad   Sellavir   Total 
Sales  $2,618   $127,000   $129,618 
Cost of goods sold   348    86,940    87,288 
Gross profit   2,270    40,060    42,330 
                
Expenses:               
General & administrative   32,335    101,786    134,121 
Professional and consulting fees   45,600    28,230    73,830 
Operating expenses   77,935    130,016    207,951 
                
Net loss from operations   (75,665)   (89,956)   (165,621)
                
Other expense - foreign currency transaction loss   -    (18,241)   (18,241)
Other income - interest - related party   -    2,406    2,406 
                
Net loss  $(75,665)  $(105,791)  $(181,456)

 

Management’s Plan to Address Going Concern Considerations

 

The Company has experienced recurring operating losses, primarily due to limited revenues. The Company’s current financial conditions and recurring losses raise substantial doubt about its ability to continue as a going concern.

 

Management intends to fund operations through existing cash balances, revenues generated from operations, related party support, and, if necessary, additional capital raises or strategic financing arrangements. There can be no assurance that such financing will be available on acceptable terms or at all.

 

Consolidated Totals:

 

Three months ended September 30, 2026 compared with the three months ended September 30, 2025

 

Revenues. Our revenues decreased $22,563, or 36.12%, to $39,906 for the three months ended September 30, 2026, compared with $62,469 for the three months ended September 30, 2025. The reduction was primarily attributable to the phase-out of Quarta-Rad sales and the timing of consulting projects and revenue recognized by Sellavir.

 

Cost of Goods Sold. Our cost of goods sold decreased $9,254, or 27.47%, to $24,428 for the three months ended September 30, 2026, compared with $33,682 for the three months ended September 30, 2025. The decrease was primarily due to the decrease of revenue.

 

Operating Expenses. Our operating expenses decreased $38,799, or 40.95%, to $55,948 for the three months ended September 30, 2026, compared with $94,747 for the three months ended September 30, 2025. General and administrative expenses were $34,748 versus $75,046, and professional and consulting fees were $21,200 versus $19,701. The decrease is primarily attributable to stock compensation in Sellavir.

 

Net Loss. Our net loss decreased $24,148, or 36.24%, to $42,493 for the three months ended September 30, 2026, compared with $66,641 for the three months ended September 30, 2025. The decrease was primarily attributable to the decrease in operating expenses.

 

QUARTA-RAD

 

Three months ended September 30, 2026, compared with the three months ended September 30, 2025

 

Revenues. Our revenues decreased $1,563, or 63.30%, to $906 for the three months ended September 30, 2026, compared with $2,469 for the three months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad sales.

 

Cost of Goods Sold. Our cost of goods sold decreased $626, or 64.27%, to $348 for the three months ended September 30, 2026, compared with $974 for the three months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad sales.

 

17

 

 

Operating Expenses. Our operating expenses decreased $7,575, or 25.48%, to $22,154 for the three months ended September 30, 2026, compared with $29,729 for the three months ended September 30, 2025. General and administrative expenses were $8,954 versus $10,028, and professional and consulting fees were $13,200 versus $19,701. The decrease was primarily attributable to the phase out of Quarta-Rad’s overhead expenses.

 

Net Loss. Our net loss decreased $6,638, or 23.51%, to $21,596 for the three months ended September 30, 2026, compared with $28,234 for the three months ended September 30, 2025. The decrease was primarily attributable to the decrease in operating expenses.

 

SELLAVIR

 

Three months ended September 30, 2026, compared with the three months ended September 30, 2025

 

Revenues. Our revenues decreased $21,000, or 35.00%, to $39,000 for the three months ended September 30, 2026, compared with $60,000 for the three months ended September 30, 2025. The decrease is due to the decrease in Sellavir revenue.

 

Cost of Goods Sold. Our cost of goods sold decreased $8,628, or 26.38%, to $24,080 for the three months ended September 30, 2026, compared with $32,708 for the three months ended September 30, 2025. The decrease is due to the decrease in Sellavir revenue recognition.

 

Operating Expenses. Our operating expenses decreased $31,224, or 48.02%, to $33,794 for the three months ended September 30, 2026, compared with $65,018 for the three months ended September 30, 2025. The decrease is primarily attributable to the decrease in stock based compensation recognized in 2025.

 

Net Loss. Our net loss decreased $17,510, or 45.59%, to $20,897 for the three months ended September 30, 2026, compared with $38,407 for the three months ended September 30, 2025. The decrease was primarily attributable to the decrease in operating expenses.

 

Consolidated Totals:

 

Nine months ended September 30, 2026 compared with the nine months ended September 30, 2025

 

Revenues. Our revenues decreased $33,068, or 20.33%, to $129,618 for the nine months ended September 30, 2026, compared with $162,686 for the nine months ended September 30, 2025. The reduction was primarily attributable to the phase-out of Quarta-Rad sales and the timing of consulting projects and revenue recognized by Sellavir.

 

Cost of Goods Sold. Our cost of goods sold decreased $10,243, or 10.50%, to $87,288 for the nine months ended September 30, 2026, compared with $97,531 for the corresponding period in 2025. The decrease was primarily due to the decrease in sales.

 

Operating Expenses. Our operating expenses decreased $99,629, or 32.39%, to $207,951 for the nine months ended September 30, 2026, compared with $307,580 for the nine months ended September 30, 2025. The decrease is primarily attributable to the decrease in administrative expenses and stock based compensation.

 

Net Loss. Our net loss decreased $34,689, or 16.05%, to $181,456 for the nine months ended September 30, 2026, compared with $216,145 for the nine months ended September 30, 2025. The decrease is primarily attributable to the decrease in administrative expenses.

 

QUARTA-RAD

 

Nine months ended September 30, 2026, compared with the nine months ended September 30, 2025

 

Revenues. Our revenues decreased $5,068, or 65.94%, to $2,618 for the nine months ended September 30, 2026, compared with $7,686 for the nine months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad sales.

 

Cost of Goods Sold. Our cost of goods sold decreased $3,461, or 90.86%, to $348 for the nine months ended September 30, 2026, compared with $3,809 for the nine months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad sales.

 

18

 

 

Operating Expenses. Our operating expenses decreased $52,037, or 40.04%, to $77,935 for the nine months ended September 30, 2026, compared with $129,972 for the nine months ended September 30, 2025. The decrease was primarily attributable to the phase out of Quarta-Rad’s overhead expenses.

 

Net Loss. Our net loss decreased $50,430, or 39.99%, to $75,665 for the nine months ended September 30, 2026, compared with $126,095 for the nine months ended September 30, 2025. The decrease is primarily attributable to the decrease in administrative expenses.

 

SELLAVIR

 

Nine months ended September 30, 2026, compared with the nine months ended September 30, 2025

 

Revenues. Our revenues decreased $28,000, or 18.06%, to $127,000 for the nine months ended September 30, 2026, compared with $155,000 for the nine months ended September 30, 2025. The decrease is due to the decrease in Sellavir revenue recognition.

 

Cost of Goods Sold. Our cost of goods sold decreased $6,782, or 7.24%, to $86,940 for the nine months ended September 30, 2026, compared with $93,722 for the nine months ended September 30, 2025. The decrease is due to the decrease in Sellavir revenue recognition.

 

Operating Expenses. Our operating expenses decreased $47,592, or 26.80%, to $130,016 for the nine months ended September 30, 2026, compared with $177,608 for the nine months ended September 30, 2025. The decrease is primarily attributable to the decrease in stock based compensation recognized in 2025.

 

Net Loss. Our net loss increased $15,741, or 17.48%, to $105,791 for the nine months ended September 30, 2026, compared with $90,050 for the nine months ended September 30, 2025. The increase in net loss was primarily attributable to lower revenues and the unfavorable change in foreign currency transaction results, partially offset by a decrease in operating expenses.

 

Liquidity and Capital Resources. During the three and nine months ended September 30, 2026, we used cash for operating expenses from cash on hand and consulting revenue from Sellavir.

 

Our total assets were $352,290 and $413,511 as of September 30, 2026 and December 31, 2025, respectively. Cash was $19,955 and $72,909, respectively. The related party note, including its current portion, and accrued interest totaled $300,343 and $316,178, respectively. The Thai corporation is an entity of which our Chief Executive Officer serves as Chief Executive Officer and holds a minority interest.

 

That note is secured by undeveloped land located in Thailand. Under amendments entered into in January 2024 and May 2025, principal payments are deferred until April 1, 2027, with quarterly payments thereafter through April 1, 2031, and interest is payable at maturity. The Company has received no principal payments since April 2024 and ceased recognizing interest income on the note as of March 31, 2025 due to uncertainty regarding collectability. Accordingly, this asset is not available to fund operations in the near term, and there can be no assurance as to the amount or timing of any recovery.

 

Our working capital deficit was $334,628 and $216,617 as of September 30, 2026 and December 31, 2025, respectively. Current assets were $56,583 and $72,912, while current liabilities were $391,211 and $289,529, respectively. The deficit increased $118,011. Stockholders’ deficit was $38,921 at September 30, 2026, compared with equity of $123,982 at December 31, 2025.

 

Net cash used in operating activities was $52,954 and $29,913 for the nine months ended September 30, 2026 and 2025, respectively, an increase of $23,041, or 77.02%.

 

There were no cash flows from investing activities for the nine months ended September 30, 2026 and 2025.

 

19

 

 

There were no cash flows from financing activities for the nine months ended September 30, 2026 and 2025. The cash flow statements classify changes in related party payables within operating activities.

 

The Company had no formal long-term lines of credit or other bank financing arrangements as of September 30, 2026.

 

The Company has no current plans for the purchase or sale of any plant or equipment.

 

The Company has no current plans to make any changes in the number of employees

 

The Company’s financial assets include significant receivables from related parties and other counterparties, including a related party note denominated in Thai baht, accrued interest receivable, and a long-term trade receivable. Collection of these amounts is subject to counterparty credit risk and, in the case of the Thai baht-denominated note, foreign currency exchange rate fluctuations. The Company evaluates these receivables for expected credit losses under ASC 326. Delays in collection or deterioration in the financial condition of the counterparties could adversely affect the Company’s liquidity and financial position.

 

Impact of Inflation

 

The Company believes that inflation has had a negligible effect on operations over the past quarter

 

Capital Expenditures

 

The Company expended no amounts on capital expenditures for the three and nine months ended September 30, 2026.

 

Plan of Operation

 

Our business strategy has evolved from primarily marketing radiation detection products to focusing on the development and commercialization of CenterEye, our proprietary AI-driven call center software platform. We aim to enhance call center efficiency, operational visibility, and customer engagement through advanced analytics, automation, and monitoring solutions. While we continue to maintain our online presence related to our historical product lines, management’s primary efforts are directed toward software development, marketing, and establishing strategic relationships with businesses requiring advanced customer service and operational analytics platforms.

 

While we continue to maintain our website at www.quartarad.com, we have increased our focus on Sellavir’s operations and related marketing efforts as part of our long-term business strategy.

 

During December 2020, Quarta-Rad acquired Sellavir, Inc., a Delaware corporation under common control, as a wholly owned subsidiary in exchange for 333,333 shares of common stock. The value of the shares issued was approximately $170,000 on the date of issuance.

 

Sellavir is an AI software and analytics company focused on advanced operational analytics, image processing, and call center software technologies. Sellavir’s platform utilizes artificial intelligence (“AI”) and proprietary technologies designed to assist organizations in analyzing operational and video-based data to improve business performance and customer engagement.

 

Sellavir, Inc., our wholly-owned subsidiary, is currently focused on the continued development and commercialization of CenterEye, a call center software platform that leverages AI and advanced analytics to improve call center operations. CenterEye is designed to provide real-time insights, operational metrics, monitoring capabilities, and customer engagement tools intended to improve efficiency and customer satisfaction.

 

Management is actively pursuing opportunities in Japan, the United States, and other international markets through reseller relationships and direct marketing efforts.

 

We intend to implement the following tasks within the next twelve months:

 

Software Development:

 

We intend to continue investing in the development and enhancement of CenterEye to meet the evolving needs of the call center industry. This includes adding new features, improving user experience, enhancing reporting and analytics capabilities, and improving scalability and platform functionality.

 

Marketing:

 

(Estimated cost $25,000 - $75,000). We intend to increase our marketing efforts to generate additional leads, reseller opportunities, and customer relationships for CenterEye and related software solutions. Marketing efforts may include digital advertising, website enhancements, promotional materials, and attendance at industry-related events and conferences

 

Partnerships and Client Acquisition:

 

(Estimated cost $20,000). We intend to pursue strategic relationships with call center operators, technology providers, and resellers. Management intends to focus on pilot projects, reseller arrangements, and initial software deployments designed to demonstrate the effectiveness of CenterEye and support future recurring revenue opportunities.

 

20

 

 

Historical Product Operations:

 

While the Company continues to maintain limited activities associated with its historical radiation detection product business, management’s primary operational focus has shifted toward AI-driven software and analytics solutions.

 

Our management does not currently anticipate the need to hire additional full-time employees over the next three months, as the services currently provided by our officers, directors, and independent contractors are expected to be sufficient for current operations. As our software development and commercialization activities expand, we may engage additional independent contractors or consultants to support development, marketing, operational, or business development activities.

 

We currently do not own material equipment that we intend to sell in the near future, do not have any off-balance sheet arrangements, and have not paid material expenses on behalf of our directors outside the ordinary course of business

 

Off-Balance Sheet Arrangements

 

None.

 

Forward Looking Statements

 

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report include forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (collectively, the “Reform Act”). The Reform Act provides a safe harbor for forward-looking statements to encourage companies to provide prospective information about themselves so long as they identify these statements as forward-looking and provide meaningful cautionary statements identifying important factors that could cause actual results to differ from the projected results. All statements, other than statements of historical fact that we make in this Quarterly Report on Form 10-Q, are forward-looking. The words “anticipates,” “believes,” “expects,” “intends,” “will continue,” “estimates,” “plans,” “projects,” the negative of these terms and similar expressions are intended to identify forward-looking statements. However, the absence of these words does not mean the statement is not forward-looking.

 

Forward-looking statements involve risks, uncertainties or other factors which may cause actual results to differ materially from the future results, performance or achievements expressed or implied by the forward-looking statements. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Certain risks, uncertainties or other important factors are detailed in this Quarterly Report on Form 10-Q and may be detailed from time to time in other reports we file with the Securities and Exchange Commission, including on Forms 8-K and 10-K.

 

We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for us to predict all those risks, nor can we assess the impact of all those risks on our business or the extent to which any factor may cause actual results to differ materially from those contained in any forward-looking statement. We believe these forward-looking statements are reasonable. However, you should not place undue reliance on any forward-looking statements, which are based on current expectations. Further, forward-looking statements speak only as of the date they are made, and unless required by law, we expressly disclaim any obligation or undertaking to update publicly any of them considering new information or future events.

 

Critical Accounting Policies

 

Our condensed financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, and Note 3 to the Condensed and Consolidated Financial Statements in this Form 10-Q.

 

21

 

 

The Company’s receivables consist primarily of amounts due from related parties, long-term notes receivable, and trade accounts receivable. These balances include receivables from STAR, a note receivable denominated in Thai baht, and a long-term trade receivable. Accounts and notes receivable are stated at amortized cost, net of any applicable allowance for credit losses.

 

Management evaluates the collectibility of these receivables in accordance with ASC 326, Financial Instruments—Credit Losses, considering factors such as historical collection experience, the financial condition and creditworthiness of the counterparties, contractual payment terms, current economic conditions, and reasonable and supportable forecasts. Changes in estimated credit losses are recognized in earnings through adjustments to the allowance for credit losses. Receivables deemed uncollectible are written off against the allowance.

 

A reserve for sales returns and allowances is considered immaterial and, as a result, there was no reserve for sales returns and allowances at September 30, 2026 and December 31, 2025, respectively.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

 

Item 4. Controls and Procedures

 

Disclosure of controls and procedures.

 

The Company is responsible for establishing and maintaining adequate internal control over financial reporting in accordance with the Rule 13a-15 of the Securities Exchange Act of 1934. The Company’s officer, its president, conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of September 30, 2026 based on the criteria establish in Internal Control Integrated Framework issued by the 2013 Committee of Sponsoring Organizations of the Treadway Commission. Based on the foregoing evaluation, we concluded that our disclosure controls and procedures were not effective as of September 30, 2026 and were not effective to ensure that information required to be disclosed by the Company in reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to the Company’s management, including its Chief Executive and Principal Accounting & Financial Officers as appropriate to allow timely decisions regarding required disclosure.

 

The material weaknesses relate to the following:

 

  ● We do not have adequate segregation of duties in the handling of our financial reporting. This is caused by a very limited number of personnel.
     
  ● Our accounting staff does not have sufficient technical accounting knowledge relating to accounting for income taxes and complex US GAAP matters.
     
  ● The Company has not performed a risk assessment and mapped our process to control objectives.
     
  ● The Company has not implemented comprehensive entity-level internal controls.
     
  ● The Company has not implemented adequate system and manual controls.

 

Plan for Remediation of Material Weaknesses

 

We intend to take appropriate and reasonable steps to make the necessary improvements to remediate this deficiency as resources to do so become available. We intend to consider the results of our remediation efforts and related testing as part of our year-end 2026 assessment of the effectiveness of our internal control over financial reporting.

 

Such remediation would entail enhancing the training and oversight of the accounting personnel responsible for non-routine transactions involving complex accounting matters and engaging the services of an independent consultant with sufficient expertise in income tax and complex U.S. GAAP matters to assist us in the preparation of our financial statements.

 

Management believes that the aforementioned material weaknesses did not impact our financial reporting or result in a material misstatement of our condensed financial statements.

 

Changes in internal controls over financial reporting.

 

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

22

 

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None.

 

Item 1A. Risk Factors

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

None

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

  (a) The following exhibits are filed with this quarterly report on Form 10-Q or are incorporated herein by reference:

 

Exhibit    
Number   Description
     
31.1   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934*.
     
31.2   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934*.
     
32.1   Certification of the Chief Executive Officer pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*.
     
32.2   Certification of the Chief Financial Officer pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*.
     
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase
101.PRE*   Inline XBRL Taxonomy Presentation Linkbase
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

23

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  QUARTA-RAD, INC.
   
Dated: November 16, 2026 [s] Victor Shvetsky
  Victor Shvetsky
  Chairman and Chief Executive Officer (Principal Executive
  Officer) and Chief Financial Officer (Principal Accounting and Financial Officer)

 

  [s] Dmitry Choulindin
 

Dmitry Choulindin

Director

 

24